Evidence map›Paper›PMID 38167018›Full record

ArticleBMC cancer2024

RACGAP1 promotes the progression and poor prognosis of lung adenocarcinoma through its effects on the cell cycle and tumor stemness.

Yafeng Liu, Tao Han, Rui Miao, Jiawei Zhou, Jianqiang Guo, Zhi Xu, Yingru Xing, Ying Bai, Jing Wu, Dong Hu

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Diethyldithiocarbamate-CuNanomedicine (London, England) · 2025
    Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Yafeng Liu *School of Medicine, Anhui University of Science and Technology, Chongren Building, No 168, Taifeng St, Huainan, 232001, P.R. China.
Tao Han *School of Medicine, Anhui University of Science and Technology, Chongren Building, No 168, Taifeng St, Huainan, 232001, P.R. China.
Rui Miao *School of Medicine, Anhui University of Science and Technology, Chongren Building, No 168, Taifeng St, Huainan, 232001, P.R. China.
Jiawei ZhouSchool of Medicine, Anhui University of Science and Technology, Chongren Building, No 168, Taifeng St, Huainan, 232001, P.R. China.
Jianqiang GuoSchool of Medicine, Anhui University of Science and Technology, Chongren Building, No 168, Taifeng St, Huainan, 232001, P.R. China.
Zhi XuSchool of Medicine, Anhui University of Science and Technology, Chongren Building, No 168, Taifeng St, Huainan, 232001, P.R. China.
Yingru XingSchool of Medicine, Anhui University of Science and Technology, Chongren Building, No 168, Taifeng St, Huainan, 232001, P.R. China.
Ying BaiSchool of Medicine, Anhui University of Science and Technology, Chongren Building, No 168, Taifeng St, Huainan, 232001, P.R. China. by0319_cpu@163.com.
Jing WuSchool of Medicine, Anhui University of Science and Technology, Chongren Building, No 168, Taifeng St, Huainan, 232001, P.R. China. wujing8008@126.com.
Dong HuSchool of Medicine, Anhui University of Science and Technology, Chongren Building, No 168, Taifeng St, Huainan, 232001, P.R. China. austhudong@126.com.
Anhui University of Science and Technology · CN

Funding

Anhui Province Engineering Laboratory of Occupational Health and Safety AYZJSGCLK202201001, AYZJSGCLK202201002, AYZJSGCLK 202202001Key Laboratory of Industrial Dust Deep Reduction and Occupational Health and Safety of Anhui Higher Education Institutes AYZJSGXLK202202002Scientific Research Foundation for High-level Talents of Anhui University of Science and Technology 2022y jrc14the Collaborative Innovation Project of Colleges and Universities of Anhui Province GXXT-2020-058the Innovation and Entrepreneurship Project of Anhui University of Science and Technology 2021CX2125, 2021CX2126, 2021CX2124the National Natural Science Foundation of China 81971483
6 · The paper itself

Abstract

objectionInvestigating the key genes and mechanisms that influence stemness in lung adenocarcinoma.

methodsFirst, consistent clustering analysis was performed on lung adenocarcinoma patients using stemness scoring to classify them. Subsequently, WGCNA was utilized to identify key modules and hub genes. Then, machine learning methods were employed to screen and identify the key genes within these modules. Lastly, functional analysis of the key genes was conducted through cell scratch assays, colony formation assays, transwell migration assays, flow cytometry cell cycle analysis, and xenograft tumor models.

resultsFirst, two groups of patients with different stemness scores were obtained, where the high stemness score group exhibited poor prognosis and immunotherapy efficacy. Next, LASSO regression analysis and random forest regression were employed to identify genes (PBK, RACGAP1) associated with high stemness scores. RACGAP1 was significantly upregulated in the high stemness score group of lung adenocarcinoma and closely correlated with clinical pathological features, poor overall survival (OS), recurrence-free survival (RFS), and unfavorable prognosis in lung adenocarcinoma patients. Knockdown of RACGAP1 suppressed the migration, proliferation, and tumor growth of cancer cells.

conclusionRACGAP1 not only indicates poor prognosis and limited immunotherapy benefits but also serves as a potential targeted biomarker influencing tumor stemness.

Indexed as

Adenocarcinoma of LungLung NeoplasmsCell CycleCell DivisionGTPase-Activating ProteinsHumansPrognosisGTPase-Activating ProteinsmgcRacGAPCell cycleLUADPrognosisRACGAP1Tumor stemness

Identifiers

PMID38167018
PMCPMC10763365
OpenAlexW4390510701

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.